Table 2.
Clinical trials of CAR-NK cell-based cancer immunotherapy
| Rank | Status | Study Title | Conditions | Interventions | Phase | Number Enrolled | NCT Number | Study Complete | Location |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Recruiting | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients with Solid Tumors | Solid Tumor | Biological: ROBO1 CAR-NK cells | Phase 1, Phase 2 | 20 | NCT03940820 | May-2022 | China |
| 2 | Unknown | Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients with Metastatic Solid Tumours | Solid Tumor | Biological: CAR-NK cells targeting NKG2D ligands | Phase 1 | 30 | NCT03415100 | Dec-2019 | China |
| 3 | Recruiting | Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients with Malignant Tumor | Malignant Tumor | Biological: BiCAR-NK/T cells (ROBO1 CAR-NK/T cells) | Phase 1, Phase 2 | 20 | NCT03931720 | May-2022 | China |
| 4 | Not yet recruiting | Study of Anti-PSMA CAR NK Cell in Castration-Resistant Prostate Cancer | Castration-resistant Prostate Cancer | Biological: anti-PSMA CAR NK cells | Early Phase 1 | 9 | NCT03692663 | Dec-2021 | |
| 5 | Not yet recruiting | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects with Recurrent/ Metastatic Gastric or Head and Neck Cancer | Gastroesophageal Junction (GEJ) Cancers; Advanced HNSCC | Drug: N-803; Drug: Pembrolizumab; Biological: PD-L1t-haNK | Phase 2 | 55 | NCT04847466 | Dec-2025 | United States |
| 6 | Not yet recruiting | Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer | Epithelial Ovarian Cancer | Biological: anti-Mesothelin Car-NK cells | Early Phase 1 | 30 | NCT03692637 | Nov-2021 | |
| 7 | Recruiting | Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients with Pancreatic Cancer | Pancreatic Cancer | Biological: BiCAR-NK cells (ROBO1 CAR-NK cells) | Phase 1, Phase 2 | 9 | NCT03941457 | May-2022 | China |
| 8 | Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers |
Lymphoma, Non-Hodgkin; B-cell Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
Biological: NKX019 | Phase 1 | 60 | NCT05020678 | Jul-2038 | United States; Australia |
| 9 | Recruiting | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non-Hodgkin’s Lymphoma | Drug: Fludarabine; Cyclophosphamide; CAR-NK-CD19 cells | Phase 1 | 27 | NCT04796675 | Mar-2024 | China |
| 10 | Recruiting | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | B-Lymphoid Malignancies; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma | Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Mesna; | Phase 1, Phase 2 | 36 | NCT03056339 | Jun-2022 | United States |
| 11 | Recruiting | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19 + Relapsed/Refractory Hematological Malignancies | Acute Lymphoblastic Leukemia; Chronic Lymphoblastic Leukemia; B-cell Lymphoma | Drug: Fludarabine; Cyclophosphamide; CAR-NK-CD19 cells | Phase 1 | 27 | NCT04796688 | Mar-2024 | China |
| Rank | Status | Study Title | Conditions | Interventions | Phase | Number Enrolled | NCT Number | Study Complete | Location |
| 12 | Not yet recruiting | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | Multiple Myeloma, Refractory | Biological: Anti-BCMA CAR-NK Cells; Drug: Fludarabine; Drug: Cytoxan | Early Phase 1 | 27 | NCT05008536 | Sep-2023 | China |
| 13 | Recruiting | NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults with AML or MDS | Relapsed/Refractory AML; AML, Adult MDS; Refractory Myelodysplastic Syndromes | Biological: NKX101 - CAR NK cell therapy | Phase 1 | 64 | NCT04623944 | Jul-2038 | United States; |
| 14 | Not yet recruiting | Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | Leukemia, Myeloid, Acute | Biological: anti-CD33 CAR NK cells; Drug: Fludarabine; Drug: Cytoxan | Phase 1 | 27 | NCT05008575 | Sep-2023 | China |
| 15 | Unknown | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | Acute Myelogenous Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia with Maturation | Biological: anti-CD33 CAR-NK cells | Phase 1, Phase 2 | 10 | NCT02944162 | Sep-2018 | China |
| 16 | Recruiting | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | Multiple Myeloma | Biological: BCMA CAR-NK 92 cells | Phase 1, Phase 2 | 20 | NCT03940833 | May-2022 | China |
| 17 | Not yet recruiting | Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | Refractory B-Cell Lymphoma | Biological: Anti-CD22 CAR NK Cells | Early Phase 1 | 9 | NCT03692767 | Nov-2021 | |
| 18 | Not yet recruiting | Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | Refractory B-Cell Lymphoma | Biological: Anti-CD19 CAR NK Cells | Early Phase 1 | 9 | NCT03690310 | Nov-2021 | |
| 19 | Not yet recruiting | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | NHL | Biological: anti-CD19 CAR NK | Early Phase 1 | 9 | NCT04639739 | Dec-2023 | China |
| 20 | Recruiting | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | B-cell Non-Hodgkin Lymphoma | Biological: anti-CD19 CAR-NK | Phase 1 | 25 | NCT04887012 | May-2024 | China |
| 21 | Unknown | Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | Refractory B-Cell Lymphoma | Biological: Anti-CD19/CD22 CAR NK Cells | Early Phase 1 | 10 | NCT03824964 | Jan-2021 | |
| 22 | Unknown | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients with CD19 Positive Leukemia and Lymphoma | Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma | Biological: anti-CD19 CAR-NK cells | Phase 1, Phase 2 | 10 | NCT02892695 | Sep-2019 | China |
| 23 | Withdrawn | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | CD19 Positive Mantle Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma | Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Carmustine; Drug: Cytarabine | Phase 1, Phase 2 | 0 | NCT03579927 | Oct-2019 | United States |